Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Frontline Ltd., a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2021, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Hamilton, Bermuda.

Frontline Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

100% OF PATIENTS IN COHORTS 1-3 REMAIN FREE OF CYTOKINE RELEASE SYNDROME CRIS-7-DERIVED CD3 DESIGN UNDERPINS A CONTROLLED T-CELL RESPONSE, SUPPORTING THE DIFFERENTIATED SAFETY PROFILE, COMBINABILITY WITH STANDARD OF CARE SEATTLE, WA / ACCESS NEWSWIRE / DECEMBER 9, 2025 / APTEVO THERAPEUTICS INC. (NASDAQ:APVO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL IMMUNE-ONCOLOGY THERAPEUTICS BASED ON ITS PROPRIETARY ADAPTIR AND ADAPTIR-FLEX PLATFORM TECHNOLOGIES, PRESENTED PRELIMINARY RESULTS FROM ITS ONGOING PHASE 1B/2 RAINIER STUDY EVALUATING MIPLETAMIG, A CD123 X CD3 BISPECIFIC MOLECULE, IN COMBINATION WITH AZACITIDINE AND VENETOCLAX (AZA/VEN) FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY. THE DATA WERE PRESENTED ON DECEMBER 8, 2025, IN A POSTER SESSION AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING.

APTEVO THERAPEUTICS HIGHLIGHTS COMPELLING SAFETY AND STRONG REMISSION RATES FOR MIPLETAMIG IN FRONTLINE AML AT ASH 2025

ALL THREE DOSE GROUPS (50 MG, 100 MG AND 200 MG) SHOWED IMPRESSIVE MONOTHERAPY EFFICACY, WITH VGPR+ (VERY GOOD PARTIAL RESPONSE OR BETTER) OF 70% DESPITE LIMITED FOLLOW-UP; EVIDENCE SHOWS THAT THESE RESPONSES ARE EXPECTED TO DEEPEN OVER TIME

LYNOZYFIC (LINVOSELTAMAB) MONOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) SHOWS IMPRESSIVE RESPONSES, SUPPORTING RATIONALE AS A POTENTIAL FOUNDATION IN FRONTLINE TREATMENT

FRONTLINE PLC REPORTS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 FRONTLINE PLC (THE COMPANY, FRONTLINE, WE, US, OR OUR), TODAY REPORTED UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025: HIGHLIGHTS PROFIT OF $40.3 MILLION, OR $0.18 PER SHARE FOR THE THIRD QUARTER OF 2025. ADJUSTED PROFIT OF $42.5 MILLION, OR $0.19 PER SHARE FOR THE THIRD QUARTER OF 2025.

FRO  THIRD QUARTER AND NINE MONTHS 2025 RESULTS

INVESTOR EVENT IN NEW YORK CITY TO PROVIDE UPDATE ON PIVOTAL PHASE 3 STUDY OF IMNN-001; OFFERING IN-PERSON OR VIRTUAL ATTENDANCE ON NOVEMBER 10, 2025

IMUNON ANNOUNCES WEBCAST OF IN-PERSON R&D DAY HIGHLIGHTING PROGRESS ON OVATION 3 STUDY IN PURSUIT OF FIRST FRONTLINE IMMUNOTHERAPY FOR ADVANCED OVARIAN CANCER

INVESTOR EVENT TO PROVIDE UPDATE ON PIVOTAL PHASE 3 STUDY OF IMNN-001 TO BE HELD IN NEW YORK CITY ON NOVEMBER 10, 2025 PROGRAM WILL FEATURE PRESENTATIONS FROM OVARIAN CANCER THOUGHT LEADERS, PHASE 3 STUDY INVESTIGATORS, ONCOLOGY AND STATISTICAL EXPERTS LAWRENCEVILLE, N.J., OCT. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT IT WILL HOST AN R&D DAY FOR INVESTORS AT THE HARVARD CLUB (35 WEST 44TH STREET) IN NEW YORK CITY ON NOVEMBER 10, 2025, BEGINNING AT 8:00 A.M.

IMUNON HOSTS R&D DAY HIGHLIGHTING PROGRESS ON OVATION 3 STUDY IN PURSUIT OF FIRST FRONTLINE IMMUNOTHERAPY FOR ADVANCED OVARIAN CANCER

COMPACT, CONNECTED CAMERA BUILT TO SAFEGUARD FRONTLINE WORKERS WITHBI-DIRECTIONAL COMMUNICATIONS, EXTENDED BATTERY LIFE AND AI-ENABLED ASSISTANCE SCOTTSDALE,ARIZ., SEPT. 29, 2025 /PRNEWSWIRE/ -- AXON (NASDAQ: AXON), THE GLOBAL LEADER IN PUBLIC SAFETY TECHNOLOGY, TODAY UNVEILS AXON BODY WORKFORCE MINI (ABW MINI), THE NEWEST ADDITION TO ITS ENTERPRISE-FOCUSED BODY CAMERA LINE, PURPOSE-BUILT FOR RETAIL, HEALTHCARE, AND OTHER FRONTLINE WORKERS TO BETTER PROTECT PEOPLE AND PROPERTY.

AXON UNVEILS AXON BODY WORKFORCE MINI TO PROTECT FRONTLINE WORKERS AND BUSINESSES AMID RISING VIOLENCE AND THEFT

BASKING RIDGE, N.J., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- A NEW STUDY RELEASED TODAY BY VERIZON REVEALS THAT NEARLY HALF OF FIRST RESPONDERS ANTICIPATE DAILY USE OF ARTIFICIAL INTELLIGENCE (AI) AND DRONES OR ROBOTS WITHIN THE NEXT FIVE YEARS*. THE VERIZON FRONTLINE PUBLIC SAFETY COMMUNICATIONS SURVEY ALSO HIGHLIGHTS INCREASED INVESTMENT IN CYBERSECURITY PROTECTIONS AND A GROWING DEMAND FOR HIGHLY-RELIABLE NETWORK CONNECTIVITY, WITH 78% OF FIRST RESPONDERS SURVEYED REPORTING THAT ACCESS TO A RELIABLE AND RESILIENT NETWORK HAS RESULTED IN BETTER COMMUNICATIONS IN THE FIELD.

VERIZON FRONTLINE STUDY: AI, CYBERSECURITY, DRONES & ROBOTS ARE CRITICAL AREAS FOR FIRST RESPONDERS

PROGRAM DESIGNED TO PUT A SECURE, 5G SMARTPHONE IN EVERY OFFICER'S HAND PROGRAM DESIGNED TO PUT A SECURE, 5G SMARTPHONE IN EVERY OFFICER'S HAND

TAMPA POLICE DEPARTMENT LAUNCHES CONNECTED OFFICER PROGRAM WITH VERIZON FRONTLINE

FRONTLINE PLC REPORTS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 FRONTLINE PLC (THE COMPANY, FRONTLINE, WE, US, OR OUR), TODAY REPORTED UNAUDITED RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025: HIGHLIGHTS PROFIT OF $77.5 MILLION, OR $0.35 PER SHARE FOR THE SECOND QUARTER OF 2025. ADJUSTED PROFIT OF $80.4 MILLION, OR $0.36 PER SHARE FOR THE SECOND QUARTER OF 2025.

FRO  SECOND QUARTER AND SIX MONTHS 2025 RESULTS

WAYNE, PA., AUG. 20, 2025 (GLOBE NEWSWIRE) -- FRONTLINE EDUCATION, THE LEADING PROVIDER OF ADMINISTRATION SOFTWARE PURPOSE-BUILT FOR K-12, TODAY ANNOUNCED THE LAUNCH OF ITS DEAR FUTURE CAMPAIGN  A POWERFUL EXPRESSION OF THE COMPANY'S AI VISION AND COMMITMENT TO DRIVING THE NEXT ERA OF INNOVATION FOR SCHOOL DISTRICT OPERATIONS, BUILT IN CLOSE PARTNERSHIP WITH K-12 LEADERS TO ENSURE PROGRESS IS GUIDED BY THE VOICES OF THOSE IT SERVES.

FRONTLINE EDUCATION LAUNCHES AI VISION, BROUGHT TO LIFE BY DEAR FUTURE CAMPAIGN

SAFETY REVIEW COMMITTEE ENDORSES ESCALATION TO 160 MG TUS DOSING COHORTS WITH 120 MG, 80 MG, 40 MG TUS DOSING COMPLETED WITH NO DOSE-LIMITING TOXICITIES EXCELLENT SAFETY AND COMPLETE REMISSIONS (CRS) IN SOME OF THE MOST DIFFICULT-TO-TREAT AML POPULATIONS NO DOSE REDUCTIONS REQUIRED TO THE STANDARD-OF-CARE VEN/AZA WITH TUS DOSE COHORTS TUS+VEN+AZA TRIPLET CONTINUES TO ACHIEVE CRS AND MINIMAL RESIDUAL DISEASE (MRD)-NEGATIVITY WITH FAVORABLE SAFETY IN NEWLY DIAGNOSED AML PATIENTS APTOSE RECEIVES THIRD ADVANCE UNDER THE LOAN AGREEMENT WITH HANMI PHARMACEUTICAL SAN DIEGO AND TORONTO, AUG. 06, 2025 (GLOBE NEWSWIRE) -- APTOSE BIOSCIENCES INC. (APTOSE OR THE COMPANY) (OTC: APTOF, TSX: APS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY DEVELOPING THE TUSPETINIB (TUS)-BASED TRIPLE DRUG FRONTLINE THERAPY TO TREAT PATIENTS WITH NEWLY DIAGNOSED AML, TODAY ANNOUNCED THAT THE COHORT SAFETY REVIEW COMMITTEE (CSRC) MONITORING APTOSE'S PHASE 1/2 TUSCANY TRIAL OF TUS IN COMBINATION WITH STANDARD OF CARE DOSING OF VENETOCLAX AND AZACITIDINE (TUS+VEN+AZA TRIPLET) HAS APPROVED ESCALATING FROM 120 MG TUS DOSE TO 160 MG TUS DOSE BASED ON ITS FAVORABLE REVIEW OF SAFETY AND EFFICACY DATA FROM PATIENTS IN THE FIRST THREE COHORTS (40 MG, 80 MG, AND 120 MG TUS DOSE LEVELS) OF THE TRIAL. ENROLLMENT IS OPEN FOR DOSING SUBJECTS AT THE 160 MG TUS DOSE LEVEL.

APTOSE ENROLLMENT IS OPEN FOR 160 MG DOSING COHORT OF TUSPETINIB IN PHASE 1/2 TUSCANY TRIAL OF FRONTLINE TRIPLE DRUG THERAPY

WAYNE, PA., JULY 28, 2025 (GLOBE NEWSWIRE) -- FRONTLINE EDUCATION, A LEADING PROVIDER OF ADMINISTRATION SOFTWARE PURPOSE-BUILT FOR K-12 EDUCATORS, TODAY ANNOUNCED THE APPOINTMENT OF JOEL SACKETT AS THE COMPANY'S NEW CHIEF PRODUCT OFFICER (CPO).

Frontline Ltd.

FRO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Frontline Ltd.

FRO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

FRO